Qualified physicians, ll within the American Heart Association 30-day All Stroke and Death rate guidelines for carotid endarterectomy of 6 % for symptomatic and 3 % for asymptomatic patients with carotid artery disease. The PROTECT study results Transcatheter Cardiovascular Therapeutics Transcatheter Cardiovascular Therapeutics conference in Washington in October 2008.. Safety and efficacy endpoints of the Emboshield Nav6 in Abbott were PROTECT trial, which is designed to examine carotid artery stenting with Abbott’s Emboshield systems in patients at high risk for endarterectomy was fulfilled.
Until now we have ultrasound and other technology to guide us in the treatment of cancers, but this is another step of precision, said Dr. Rashid Haq, Clinical Assistant Professor of Radiation Oncology at SUNY Upstate Medical University in Syracuse.
Abbott has a broad portfolio of technologies,. To help physicians develop a better treatment for their patients with peripheral arterial disease , the company is investments in endovascular therapies and educational programs and undertakes the design and implementation of endovascular clinical trials..The research part 100 samples on the normal and malignant benign prostate sampling from Australian men.
Detail the study, which resulted by Associate Professor Noel Whitaker and Professor James Lawson, the University of New South Wales in Sydney, Australia shall be published in the trade journal The Prostate.
Earlier research by Professor Whitaker the team found that HPV is good at about 40 percent all breast cancer cases as a the new study found. High risk HPV is scanned own into approximately 70 percent of malignant prostate cancer. EBV at to top and neck cancers , especially into South-East Asia in conjunction: such as HPV, it is usually distributed through a narrow Avoid contact with the skin, it are dubbed the kissing disease .